Predictors of Unexplained Early Neurological Deterioration After Endovascular Treatment for Acute Ischemic Stroke

BACKGROUND AND PURPOSE:Although the efficacy of endovascular treatment (EVT) in patients with anterior circulation ischemic stroke (AIS) is well documented, early neurological deterioration after EVT remains a serious issue associated with poor outcome. Besides obvious causes, such as lack of reperf...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Stroke (1970) 2020-10, Vol.51 (10), p.2943-2950
Hauptverfasser: Girot, Jean-Baptiste, Richard, Sébastien, Gariel, Florent, Sibon, Igor, Labreuche, Julien, Kyheng, Maéva, Gory, Benjamin, Dargazanli, Cyril, Maier, Benjamin, Consoli, Arturo, Daumas-Duport, Benjamin, Lapergue, Bertrand, Bourcier, Romain
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 2950
container_issue 10
container_start_page 2943
container_title Stroke (1970)
container_volume 51
creator Girot, Jean-Baptiste
Richard, Sébastien
Gariel, Florent
Sibon, Igor
Labreuche, Julien
Kyheng, Maéva
Gory, Benjamin
Dargazanli, Cyril
Maier, Benjamin
Consoli, Arturo
Daumas-Duport, Benjamin
Lapergue, Bertrand
Bourcier, Romain
description BACKGROUND AND PURPOSE:Although the efficacy of endovascular treatment (EVT) in patients with anterior circulation ischemic stroke (AIS) is well documented, early neurological deterioration after EVT remains a serious issue associated with poor outcome. Besides obvious causes, such as lack of reperfusion, procedural complications, or parenchymal hemorrhage, early neurological deterioration may remain unexplained (UnEND). Our aim was to investigate predictors of UnEND after EVT in patients with AIS. METHODS:Patients who underwent EVT for AIS, with an initial National Institutes of Health Stroke Scale score >5, Alberta Stroke Program Early CT Score ≥6, and included in a multicenter prospective observational registry were analyzed. Predictors of UnEND, defined as ≥4-point increase in the National Institutes of Health Stroke Scale score between baseline and day 1 after EVT, were determined via center-adjusted analyses. RESULTS:Among the 1925 included in the analysis, 128 UnEND (6.6%) were recorded. In multivariate analysis, predictors of UnEND were diabetes mellitus (odds ratio [OR], 2.17 [95% CI, 1.32–3.56]), prestroke modified Rankin Scale score ≥2 (OR, 2.22 [95% CI, 1.09–4.55]), general anesthesia (OR, 2.55 [95% CI, 1.51–4.30]), admission systolic blood pressure (OR, 1.10 [95% CI, 1.01–1.20]), age (OR, 1.38 [95% CI, 1.14–1.67]), number of passes (OR, 1.16 [95% CI, 1.04–1.28]), direct admission or not to a comprehensive stroke center (OR, 0.49 [95% CI, 0.30–0.81]), and initial National Institutes of Health Stroke Scale score (OR, 0.65 [95% CI, 0.52–0.81]). CONCLUSIONS:Severely impaired AIS patients with nonmodifiable factors are more likely to develop UnEND. Some modifiable predictors of UnEND such as the number of EVT passes could be the object of improvement in AIS management.
doi_str_mv 10.1161/STROKEAHA.120.029494
format Article
fullrecord <record><control><sourceid>pubmed_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_03280043v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>32921260</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5324-e94b495360fed801586e1b96737084cfee834000d43193d2cabe5ab97bb082bd3</originalsourceid><addsrcrecordid>eNqFkE1v1DAQhi0EokvhHyDkK4dsxx_58DEqW7bqiiK6PVuOM2FDvfFiJy3993gV2CMcLGtG7zPS-xDynsGSsYJd3G2_3d6s6nW9ZByWwJVU8gVZsJzLTBa8ekkWAEJlXCp1Rt7E-AMAuKjy1-RMcMUZL2BBfn4N2PZ29CFS39H7AX8dnOkHbOnKBPdMv-AUvPPfe2sc_YQjht4HM_Z-oHWXJroaWv9oop2cCXQb0Ix7HEba-UBrO41Ir6Pd4b639G4M_gHfkledcRHf_fnPyf3Vanu5zja3n68v601mc5EqoJKNVLkooMO2ApZXBbJGFaUooZK2Q6yETI1aKZgSLbemwdw0qmwaqHjTinPycb67M04fQr834Vl70-t1vdHHHQheAUjxyFJWzlkbfIwBuxPAQB9t65NtnWzr2XbCPszYYWr22J6gv3pToJoDT94lV_HBTU8Y9A6NG3f_uy3_gabiUBYlZBw4sOOUpce4-A0ZPZ38</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Predictors of Unexplained Early Neurological Deterioration After Endovascular Treatment for Acute Ischemic Stroke</title><source>MEDLINE</source><source>American Heart Association Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Alma/SFX Local Collection</source><source>Journals@Ovid Complete</source><creator>Girot, Jean-Baptiste ; Richard, Sébastien ; Gariel, Florent ; Sibon, Igor ; Labreuche, Julien ; Kyheng, Maéva ; Gory, Benjamin ; Dargazanli, Cyril ; Maier, Benjamin ; Consoli, Arturo ; Daumas-Duport, Benjamin ; Lapergue, Bertrand ; Bourcier, Romain</creator><creatorcontrib>Girot, Jean-Baptiste ; Richard, Sébastien ; Gariel, Florent ; Sibon, Igor ; Labreuche, Julien ; Kyheng, Maéva ; Gory, Benjamin ; Dargazanli, Cyril ; Maier, Benjamin ; Consoli, Arturo ; Daumas-Duport, Benjamin ; Lapergue, Bertrand ; Bourcier, Romain ; ETIS Investigators</creatorcontrib><description>BACKGROUND AND PURPOSE:Although the efficacy of endovascular treatment (EVT) in patients with anterior circulation ischemic stroke (AIS) is well documented, early neurological deterioration after EVT remains a serious issue associated with poor outcome. Besides obvious causes, such as lack of reperfusion, procedural complications, or parenchymal hemorrhage, early neurological deterioration may remain unexplained (UnEND). Our aim was to investigate predictors of UnEND after EVT in patients with AIS. METHODS:Patients who underwent EVT for AIS, with an initial National Institutes of Health Stroke Scale score &gt;5, Alberta Stroke Program Early CT Score ≥6, and included in a multicenter prospective observational registry were analyzed. Predictors of UnEND, defined as ≥4-point increase in the National Institutes of Health Stroke Scale score between baseline and day 1 after EVT, were determined via center-adjusted analyses. RESULTS:Among the 1925 included in the analysis, 128 UnEND (6.6%) were recorded. In multivariate analysis, predictors of UnEND were diabetes mellitus (odds ratio [OR], 2.17 [95% CI, 1.32–3.56]), prestroke modified Rankin Scale score ≥2 (OR, 2.22 [95% CI, 1.09–4.55]), general anesthesia (OR, 2.55 [95% CI, 1.51–4.30]), admission systolic blood pressure (OR, 1.10 [95% CI, 1.01–1.20]), age (OR, 1.38 [95% CI, 1.14–1.67]), number of passes (OR, 1.16 [95% CI, 1.04–1.28]), direct admission or not to a comprehensive stroke center (OR, 0.49 [95% CI, 0.30–0.81]), and initial National Institutes of Health Stroke Scale score (OR, 0.65 [95% CI, 0.52–0.81]). CONCLUSIONS:Severely impaired AIS patients with nonmodifiable factors are more likely to develop UnEND. Some modifiable predictors of UnEND such as the number of EVT passes could be the object of improvement in AIS management.</description><identifier>ISSN: 0039-2499</identifier><identifier>EISSN: 1524-4628</identifier><identifier>DOI: 10.1161/STROKEAHA.120.029494</identifier><identifier>PMID: 32921260</identifier><language>eng</language><publisher>United States: American Heart Association, Inc</publisher><subject>Aged ; Aged, 80 and over ; Bioengineering ; Brain Ischemia - drug therapy ; Brain Ischemia - therapy ; Combined Modality Therapy ; Computer Science ; Endovascular Procedures - adverse effects ; Female ; Fibrinolytic Agents - adverse effects ; Fibrinolytic Agents - therapeutic use ; Human health and pathology ; Humans ; Life Sciences ; Male ; Medical Imaging ; Middle Aged ; Nuclear medicine ; Prospective Studies ; Registries ; Risk Factors ; Stroke - drug therapy ; Stroke - therapy ; Thrombectomy - adverse effects ; Treatment Outcome</subject><ispartof>Stroke (1970), 2020-10, Vol.51 (10), p.2943-2950</ispartof><rights>American Heart Association, Inc.</rights><rights>2020 American Heart Association, Inc.</rights><rights>Distributed under a Creative Commons Attribution 4.0 International License</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5324-e94b495360fed801586e1b96737084cfee834000d43193d2cabe5ab97bb082bd3</citedby><cites>FETCH-LOGICAL-c5324-e94b495360fed801586e1b96737084cfee834000d43193d2cabe5ab97bb082bd3</cites><orcidid>0000-0003-4636-2034 ; 0000-0001-8424-4464 ; 0000-0002-6506-4019 ; 0000-0002-5650-828X ; 0000-0002-1171-4215 ; 0000-0002-0029-1835 ; 0000-0001-9788-4516 ; 0000-0001-6112-0661 ; 0000-0002-2780-6907 ; 0000-0001-9479-3598 ; 0000-0002-6704-3158 ; 0000-0003-0911-8999 ; 0000-0002-1977-5987 ; 0000-0001-9165-5763 ; 0000-0003-1306-1008 ; 0000-0002-4665-1461 ; 0000-0002-0945-5656 ; 0000-0001-5059-4095 ; 0000-0003-0632-3399 ; 0000-0002-6943-9922 ; 0000-0001-8428-9101 ; 0000-0001-8677-2447 ; 0000-0001-6352-7713 ; 0000-0002-8712-8431 ; 0000-0002-0909-8900 ; 0000-0001-6640-8541 ; 0000-0001-5801-0816 ; 0000-0002-5696-5368 ; 0000-0002-2134-0691 ; 0000-0002-2087-5563 ; 0000-0003-3911-1800 ; 0000-0002-3975-3865 ; 0000-0003-2027-2276 ; 0000-0003-2950-8759 ; 0000-0002-1354-4328 ; 0000-0001-8422-9205 ; 0000-0003-1891-9157 ; 0000-0003-0594-4409 ; 0000-0002-8915-0915 ; 0000-0002-6748-8528 ; 0000-0002-7611-7753</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>230,314,776,780,881,3674,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32921260$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.univ-lorraine.fr/hal-03280043$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Girot, Jean-Baptiste</creatorcontrib><creatorcontrib>Richard, Sébastien</creatorcontrib><creatorcontrib>Gariel, Florent</creatorcontrib><creatorcontrib>Sibon, Igor</creatorcontrib><creatorcontrib>Labreuche, Julien</creatorcontrib><creatorcontrib>Kyheng, Maéva</creatorcontrib><creatorcontrib>Gory, Benjamin</creatorcontrib><creatorcontrib>Dargazanli, Cyril</creatorcontrib><creatorcontrib>Maier, Benjamin</creatorcontrib><creatorcontrib>Consoli, Arturo</creatorcontrib><creatorcontrib>Daumas-Duport, Benjamin</creatorcontrib><creatorcontrib>Lapergue, Bertrand</creatorcontrib><creatorcontrib>Bourcier, Romain</creatorcontrib><creatorcontrib>ETIS Investigators</creatorcontrib><title>Predictors of Unexplained Early Neurological Deterioration After Endovascular Treatment for Acute Ischemic Stroke</title><title>Stroke (1970)</title><addtitle>Stroke</addtitle><description>BACKGROUND AND PURPOSE:Although the efficacy of endovascular treatment (EVT) in patients with anterior circulation ischemic stroke (AIS) is well documented, early neurological deterioration after EVT remains a serious issue associated with poor outcome. Besides obvious causes, such as lack of reperfusion, procedural complications, or parenchymal hemorrhage, early neurological deterioration may remain unexplained (UnEND). Our aim was to investigate predictors of UnEND after EVT in patients with AIS. METHODS:Patients who underwent EVT for AIS, with an initial National Institutes of Health Stroke Scale score &gt;5, Alberta Stroke Program Early CT Score ≥6, and included in a multicenter prospective observational registry were analyzed. Predictors of UnEND, defined as ≥4-point increase in the National Institutes of Health Stroke Scale score between baseline and day 1 after EVT, were determined via center-adjusted analyses. RESULTS:Among the 1925 included in the analysis, 128 UnEND (6.6%) were recorded. In multivariate analysis, predictors of UnEND were diabetes mellitus (odds ratio [OR], 2.17 [95% CI, 1.32–3.56]), prestroke modified Rankin Scale score ≥2 (OR, 2.22 [95% CI, 1.09–4.55]), general anesthesia (OR, 2.55 [95% CI, 1.51–4.30]), admission systolic blood pressure (OR, 1.10 [95% CI, 1.01–1.20]), age (OR, 1.38 [95% CI, 1.14–1.67]), number of passes (OR, 1.16 [95% CI, 1.04–1.28]), direct admission or not to a comprehensive stroke center (OR, 0.49 [95% CI, 0.30–0.81]), and initial National Institutes of Health Stroke Scale score (OR, 0.65 [95% CI, 0.52–0.81]). CONCLUSIONS:Severely impaired AIS patients with nonmodifiable factors are more likely to develop UnEND. Some modifiable predictors of UnEND such as the number of EVT passes could be the object of improvement in AIS management.</description><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Bioengineering</subject><subject>Brain Ischemia - drug therapy</subject><subject>Brain Ischemia - therapy</subject><subject>Combined Modality Therapy</subject><subject>Computer Science</subject><subject>Endovascular Procedures - adverse effects</subject><subject>Female</subject><subject>Fibrinolytic Agents - adverse effects</subject><subject>Fibrinolytic Agents - therapeutic use</subject><subject>Human health and pathology</subject><subject>Humans</subject><subject>Life Sciences</subject><subject>Male</subject><subject>Medical Imaging</subject><subject>Middle Aged</subject><subject>Nuclear medicine</subject><subject>Prospective Studies</subject><subject>Registries</subject><subject>Risk Factors</subject><subject>Stroke - drug therapy</subject><subject>Stroke - therapy</subject><subject>Thrombectomy - adverse effects</subject><subject>Treatment Outcome</subject><issn>0039-2499</issn><issn>1524-4628</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1v1DAQhi0EokvhHyDkK4dsxx_58DEqW7bqiiK6PVuOM2FDvfFiJy3993gV2CMcLGtG7zPS-xDynsGSsYJd3G2_3d6s6nW9ZByWwJVU8gVZsJzLTBa8ekkWAEJlXCp1Rt7E-AMAuKjy1-RMcMUZL2BBfn4N2PZ29CFS39H7AX8dnOkHbOnKBPdMv-AUvPPfe2sc_YQjht4HM_Z-oHWXJroaWv9oop2cCXQb0Ix7HEba-UBrO41Ir6Pd4b639G4M_gHfkledcRHf_fnPyf3Vanu5zja3n68v601mc5EqoJKNVLkooMO2ApZXBbJGFaUooZK2Q6yETI1aKZgSLbemwdw0qmwaqHjTinPycb67M04fQr834Vl70-t1vdHHHQheAUjxyFJWzlkbfIwBuxPAQB9t65NtnWzr2XbCPszYYWr22J6gv3pToJoDT94lV_HBTU8Y9A6NG3f_uy3_gabiUBYlZBw4sOOUpce4-A0ZPZ38</recordid><startdate>20201001</startdate><enddate>20201001</enddate><creator>Girot, Jean-Baptiste</creator><creator>Richard, Sébastien</creator><creator>Gariel, Florent</creator><creator>Sibon, Igor</creator><creator>Labreuche, Julien</creator><creator>Kyheng, Maéva</creator><creator>Gory, Benjamin</creator><creator>Dargazanli, Cyril</creator><creator>Maier, Benjamin</creator><creator>Consoli, Arturo</creator><creator>Daumas-Duport, Benjamin</creator><creator>Lapergue, Bertrand</creator><creator>Bourcier, Romain</creator><general>American Heart Association, Inc</general><general>American Heart Association</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>1XC</scope><orcidid>https://orcid.org/0000-0003-4636-2034</orcidid><orcidid>https://orcid.org/0000-0001-8424-4464</orcidid><orcidid>https://orcid.org/0000-0002-6506-4019</orcidid><orcidid>https://orcid.org/0000-0002-5650-828X</orcidid><orcidid>https://orcid.org/0000-0002-1171-4215</orcidid><orcidid>https://orcid.org/0000-0002-0029-1835</orcidid><orcidid>https://orcid.org/0000-0001-9788-4516</orcidid><orcidid>https://orcid.org/0000-0001-6112-0661</orcidid><orcidid>https://orcid.org/0000-0002-2780-6907</orcidid><orcidid>https://orcid.org/0000-0001-9479-3598</orcidid><orcidid>https://orcid.org/0000-0002-6704-3158</orcidid><orcidid>https://orcid.org/0000-0003-0911-8999</orcidid><orcidid>https://orcid.org/0000-0002-1977-5987</orcidid><orcidid>https://orcid.org/0000-0001-9165-5763</orcidid><orcidid>https://orcid.org/0000-0003-1306-1008</orcidid><orcidid>https://orcid.org/0000-0002-4665-1461</orcidid><orcidid>https://orcid.org/0000-0002-0945-5656</orcidid><orcidid>https://orcid.org/0000-0001-5059-4095</orcidid><orcidid>https://orcid.org/0000-0003-0632-3399</orcidid><orcidid>https://orcid.org/0000-0002-6943-9922</orcidid><orcidid>https://orcid.org/0000-0001-8428-9101</orcidid><orcidid>https://orcid.org/0000-0001-8677-2447</orcidid><orcidid>https://orcid.org/0000-0001-6352-7713</orcidid><orcidid>https://orcid.org/0000-0002-8712-8431</orcidid><orcidid>https://orcid.org/0000-0002-0909-8900</orcidid><orcidid>https://orcid.org/0000-0001-6640-8541</orcidid><orcidid>https://orcid.org/0000-0001-5801-0816</orcidid><orcidid>https://orcid.org/0000-0002-5696-5368</orcidid><orcidid>https://orcid.org/0000-0002-2134-0691</orcidid><orcidid>https://orcid.org/0000-0002-2087-5563</orcidid><orcidid>https://orcid.org/0000-0003-3911-1800</orcidid><orcidid>https://orcid.org/0000-0002-3975-3865</orcidid><orcidid>https://orcid.org/0000-0003-2027-2276</orcidid><orcidid>https://orcid.org/0000-0003-2950-8759</orcidid><orcidid>https://orcid.org/0000-0002-1354-4328</orcidid><orcidid>https://orcid.org/0000-0001-8422-9205</orcidid><orcidid>https://orcid.org/0000-0003-1891-9157</orcidid><orcidid>https://orcid.org/0000-0003-0594-4409</orcidid><orcidid>https://orcid.org/0000-0002-8915-0915</orcidid><orcidid>https://orcid.org/0000-0002-6748-8528</orcidid><orcidid>https://orcid.org/0000-0002-7611-7753</orcidid></search><sort><creationdate>20201001</creationdate><title>Predictors of Unexplained Early Neurological Deterioration After Endovascular Treatment for Acute Ischemic Stroke</title><author>Girot, Jean-Baptiste ; Richard, Sébastien ; Gariel, Florent ; Sibon, Igor ; Labreuche, Julien ; Kyheng, Maéva ; Gory, Benjamin ; Dargazanli, Cyril ; Maier, Benjamin ; Consoli, Arturo ; Daumas-Duport, Benjamin ; Lapergue, Bertrand ; Bourcier, Romain</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5324-e94b495360fed801586e1b96737084cfee834000d43193d2cabe5ab97bb082bd3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Bioengineering</topic><topic>Brain Ischemia - drug therapy</topic><topic>Brain Ischemia - therapy</topic><topic>Combined Modality Therapy</topic><topic>Computer Science</topic><topic>Endovascular Procedures - adverse effects</topic><topic>Female</topic><topic>Fibrinolytic Agents - adverse effects</topic><topic>Fibrinolytic Agents - therapeutic use</topic><topic>Human health and pathology</topic><topic>Humans</topic><topic>Life Sciences</topic><topic>Male</topic><topic>Medical Imaging</topic><topic>Middle Aged</topic><topic>Nuclear medicine</topic><topic>Prospective Studies</topic><topic>Registries</topic><topic>Risk Factors</topic><topic>Stroke - drug therapy</topic><topic>Stroke - therapy</topic><topic>Thrombectomy - adverse effects</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Girot, Jean-Baptiste</creatorcontrib><creatorcontrib>Richard, Sébastien</creatorcontrib><creatorcontrib>Gariel, Florent</creatorcontrib><creatorcontrib>Sibon, Igor</creatorcontrib><creatorcontrib>Labreuche, Julien</creatorcontrib><creatorcontrib>Kyheng, Maéva</creatorcontrib><creatorcontrib>Gory, Benjamin</creatorcontrib><creatorcontrib>Dargazanli, Cyril</creatorcontrib><creatorcontrib>Maier, Benjamin</creatorcontrib><creatorcontrib>Consoli, Arturo</creatorcontrib><creatorcontrib>Daumas-Duport, Benjamin</creatorcontrib><creatorcontrib>Lapergue, Bertrand</creatorcontrib><creatorcontrib>Bourcier, Romain</creatorcontrib><creatorcontrib>ETIS Investigators</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Hyper Article en Ligne (HAL)</collection><jtitle>Stroke (1970)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Girot, Jean-Baptiste</au><au>Richard, Sébastien</au><au>Gariel, Florent</au><au>Sibon, Igor</au><au>Labreuche, Julien</au><au>Kyheng, Maéva</au><au>Gory, Benjamin</au><au>Dargazanli, Cyril</au><au>Maier, Benjamin</au><au>Consoli, Arturo</au><au>Daumas-Duport, Benjamin</au><au>Lapergue, Bertrand</au><au>Bourcier, Romain</au><aucorp>ETIS Investigators</aucorp><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Predictors of Unexplained Early Neurological Deterioration After Endovascular Treatment for Acute Ischemic Stroke</atitle><jtitle>Stroke (1970)</jtitle><addtitle>Stroke</addtitle><date>2020-10-01</date><risdate>2020</risdate><volume>51</volume><issue>10</issue><spage>2943</spage><epage>2950</epage><pages>2943-2950</pages><issn>0039-2499</issn><eissn>1524-4628</eissn><abstract>BACKGROUND AND PURPOSE:Although the efficacy of endovascular treatment (EVT) in patients with anterior circulation ischemic stroke (AIS) is well documented, early neurological deterioration after EVT remains a serious issue associated with poor outcome. Besides obvious causes, such as lack of reperfusion, procedural complications, or parenchymal hemorrhage, early neurological deterioration may remain unexplained (UnEND). Our aim was to investigate predictors of UnEND after EVT in patients with AIS. METHODS:Patients who underwent EVT for AIS, with an initial National Institutes of Health Stroke Scale score &gt;5, Alberta Stroke Program Early CT Score ≥6, and included in a multicenter prospective observational registry were analyzed. Predictors of UnEND, defined as ≥4-point increase in the National Institutes of Health Stroke Scale score between baseline and day 1 after EVT, were determined via center-adjusted analyses. RESULTS:Among the 1925 included in the analysis, 128 UnEND (6.6%) were recorded. In multivariate analysis, predictors of UnEND were diabetes mellitus (odds ratio [OR], 2.17 [95% CI, 1.32–3.56]), prestroke modified Rankin Scale score ≥2 (OR, 2.22 [95% CI, 1.09–4.55]), general anesthesia (OR, 2.55 [95% CI, 1.51–4.30]), admission systolic blood pressure (OR, 1.10 [95% CI, 1.01–1.20]), age (OR, 1.38 [95% CI, 1.14–1.67]), number of passes (OR, 1.16 [95% CI, 1.04–1.28]), direct admission or not to a comprehensive stroke center (OR, 0.49 [95% CI, 0.30–0.81]), and initial National Institutes of Health Stroke Scale score (OR, 0.65 [95% CI, 0.52–0.81]). CONCLUSIONS:Severely impaired AIS patients with nonmodifiable factors are more likely to develop UnEND. Some modifiable predictors of UnEND such as the number of EVT passes could be the object of improvement in AIS management.</abstract><cop>United States</cop><pub>American Heart Association, Inc</pub><pmid>32921260</pmid><doi>10.1161/STROKEAHA.120.029494</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0003-4636-2034</orcidid><orcidid>https://orcid.org/0000-0001-8424-4464</orcidid><orcidid>https://orcid.org/0000-0002-6506-4019</orcidid><orcidid>https://orcid.org/0000-0002-5650-828X</orcidid><orcidid>https://orcid.org/0000-0002-1171-4215</orcidid><orcidid>https://orcid.org/0000-0002-0029-1835</orcidid><orcidid>https://orcid.org/0000-0001-9788-4516</orcidid><orcidid>https://orcid.org/0000-0001-6112-0661</orcidid><orcidid>https://orcid.org/0000-0002-2780-6907</orcidid><orcidid>https://orcid.org/0000-0001-9479-3598</orcidid><orcidid>https://orcid.org/0000-0002-6704-3158</orcidid><orcidid>https://orcid.org/0000-0003-0911-8999</orcidid><orcidid>https://orcid.org/0000-0002-1977-5987</orcidid><orcidid>https://orcid.org/0000-0001-9165-5763</orcidid><orcidid>https://orcid.org/0000-0003-1306-1008</orcidid><orcidid>https://orcid.org/0000-0002-4665-1461</orcidid><orcidid>https://orcid.org/0000-0002-0945-5656</orcidid><orcidid>https://orcid.org/0000-0001-5059-4095</orcidid><orcidid>https://orcid.org/0000-0003-0632-3399</orcidid><orcidid>https://orcid.org/0000-0002-6943-9922</orcidid><orcidid>https://orcid.org/0000-0001-8428-9101</orcidid><orcidid>https://orcid.org/0000-0001-8677-2447</orcidid><orcidid>https://orcid.org/0000-0001-6352-7713</orcidid><orcidid>https://orcid.org/0000-0002-8712-8431</orcidid><orcidid>https://orcid.org/0000-0002-0909-8900</orcidid><orcidid>https://orcid.org/0000-0001-6640-8541</orcidid><orcidid>https://orcid.org/0000-0001-5801-0816</orcidid><orcidid>https://orcid.org/0000-0002-5696-5368</orcidid><orcidid>https://orcid.org/0000-0002-2134-0691</orcidid><orcidid>https://orcid.org/0000-0002-2087-5563</orcidid><orcidid>https://orcid.org/0000-0003-3911-1800</orcidid><orcidid>https://orcid.org/0000-0002-3975-3865</orcidid><orcidid>https://orcid.org/0000-0003-2027-2276</orcidid><orcidid>https://orcid.org/0000-0003-2950-8759</orcidid><orcidid>https://orcid.org/0000-0002-1354-4328</orcidid><orcidid>https://orcid.org/0000-0001-8422-9205</orcidid><orcidid>https://orcid.org/0000-0003-1891-9157</orcidid><orcidid>https://orcid.org/0000-0003-0594-4409</orcidid><orcidid>https://orcid.org/0000-0002-8915-0915</orcidid><orcidid>https://orcid.org/0000-0002-6748-8528</orcidid><orcidid>https://orcid.org/0000-0002-7611-7753</orcidid><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 0039-2499
ispartof Stroke (1970), 2020-10, Vol.51 (10), p.2943-2950
issn 0039-2499
1524-4628
language eng
recordid cdi_hal_primary_oai_HAL_hal_03280043v1
source MEDLINE; American Heart Association Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Alma/SFX Local Collection; Journals@Ovid Complete
subjects Aged
Aged, 80 and over
Bioengineering
Brain Ischemia - drug therapy
Brain Ischemia - therapy
Combined Modality Therapy
Computer Science
Endovascular Procedures - adverse effects
Female
Fibrinolytic Agents - adverse effects
Fibrinolytic Agents - therapeutic use
Human health and pathology
Humans
Life Sciences
Male
Medical Imaging
Middle Aged
Nuclear medicine
Prospective Studies
Registries
Risk Factors
Stroke - drug therapy
Stroke - therapy
Thrombectomy - adverse effects
Treatment Outcome
title Predictors of Unexplained Early Neurological Deterioration After Endovascular Treatment for Acute Ischemic Stroke
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-03T08%3A57%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Predictors%20of%20Unexplained%20Early%20Neurological%20Deterioration%20After%20Endovascular%20Treatment%20for%20Acute%20Ischemic%20Stroke&rft.jtitle=Stroke%20(1970)&rft.au=Girot,%20Jean-Baptiste&rft.aucorp=ETIS%20Investigators&rft.date=2020-10-01&rft.volume=51&rft.issue=10&rft.spage=2943&rft.epage=2950&rft.pages=2943-2950&rft.issn=0039-2499&rft.eissn=1524-4628&rft_id=info:doi/10.1161/STROKEAHA.120.029494&rft_dat=%3Cpubmed_hal_p%3E32921260%3C/pubmed_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32921260&rfr_iscdi=true